1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Bio Preventive Medicine Corp.

Bio Preventive Medicine Corp.

6810.TWO
Bio Preventive Medicine Corp.TW flagTaipei Exchange
21.40
TWD
+0.10
- -
1.06BMarket Cap
Bio Preventive Medicine Corp.
6810.TWO
(Taipei Exchange)

Recent

price

21.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
0.03
0.06
0.04
0.35
- -
Revenue per Share
-0.2
-0.25
-1.99
-1.98
-2.03
-2.16
-2.47
- -
Basic EPS, GAAP
-0.19
-0.16
-1.43
-1.41
-5.93
-1.94
-1.9
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.59
0.41
2.42
0.34
-1.14
-2.75
-0.87
- -
Book Value per Share
0.48
0.55
5.55
3.52
3.55
3.71
11.13
- -
Tangible Book Value per Share
279
292
33
34
35
34
36
- -
Basic Weighted Avg Shares
- -
- -
- -
1
2
1
12
3
Sales/Revenue/Turnover
- -
- -
- -
-7,698.05
-3,252.69
-6,006.95
-697.44
-3,832.05
Operating Margin (%)
12
20
21
21
16
8
8
7
Depreciation Expense
-57
-73
-65
-67
-71
-73
-88
-100
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-7,709.52
-3,258.61
-6,066.64
-712.04
-3,800.8
Profit Margin (%)
89
113
146
95
76
75
345
245
Working Capital
- -
11
5
- -
113
106
102
96
LT Debt
161
183
202
138
141
140
407
307
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-51.12
-65.18
-148.35
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
27.24%
-24.53%
Free Cash Flow
- -
62.57%
43.04%
Net Income, GAAP
- -
9.21%
14.03%
Sales/Revenue/Turnover
- -
- -
-78.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
12
2025
- -
- -
- -
- -
3

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-2.16
2024
- -
- -
- -
- -
-2.47
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Immunotech Laboratories, Inc. (IMMB)
I-Mab (IMAB)
Innovation Pharmaceuticals Inc. (IPIX)
NFL Biosciences S.A. (ALNFL.PA)
CEL-SCI Corporation (CVM)
Genmab A/S (GMAB)
Business
Bio Preventive Medicine Corp (6810.TWO) develops and commercializes molecular diagnostic products and testing services for early detection and prevention of chronic diseases and cancers. The company offers in vitro diagnostic reagents and non-invasive urine tests, including the patented DNlite series such as DNlite-IVD103 and DNlite-DN_Score for monitoring diabetic kidney disease progression and diabetic nephropathy; solutions for chronic kidney disease, diabetes complications and other chronic conditions; biomarker-based diagnostics for oncology applications. Founded in 2014 as an Industrial Technology Research Institute spin-off and headquartered at 6F-1, No. 18 Taiyuan Street, Zhubei City, Hsinchu County, Taiwan, Bio Preventive Medicine operates in North America, Europe, Asia and South America markets, targeting healthcare providers, pharmaceutical partners and patients with unmet needs in precision medicine. The company maintains its focus on high-value translational research without major recent acquisitions, partnerships, funding rounds or product launches reported in the last two years.